Summary
Unable to verify the AI’s alcohol-related claims because the provided FDA label excerpts do not include alcohol/liver-drinking guidance, monitoring frequency details, or quantitative risks related to alcohol. Multiple statements appear unsupported by the supplied label text.
Category Scores
Accurate Statements
Unsupported Statements
“Lipitor (atorvastatin) and alcohol both affect the liver, which processes the drug and metabolizes alcohol.”
The provided label excerpts discuss liver dysfunction monitoring and active liver disease contraindication, but do not state that alcohol metabolizes with or alongside Lipitor hepatic processing.
“Moderate alcohol use generally doesn't cause major issues for most people on Lipitor.”
No alcohol-specific statements or thresholds are present in the supplied label excerpts.
“Heavy drinking increases risks in people taking Lipitor.”
No alcohol-specific risk statements are present in the supplied label excerpts.
“Guidelines and the FDA label advise limiting alcohol to avoid amplifying side effects like liver damage or muscle pain (myopathy) in people taking Lipitor.”
The provided label excerpts do not contain alcohol-limiting guidance or link alcohol to liver damage or myopathy.
“Lipitor prescribing information states that moderate alcohol consumption need not be avoided, but excessive intake should be.”
No such alcohol recommendations or distinctions are present in the supplied label excerpts.
“Lipitor prescribing information advises monitoring with blood tests every 6-12 months.”
The supplied label excerpt states liver function tests prior to and at 12 weeks after initiation and after dose increases, and then periodically thereafter, but provides no 6–12 month interval.
“Exceeding suggested alcohol limits, especially binge drinking, increases liver enzyme elevation risks by 2-3 times in statin users.”
No quantitative alcohol-related risk figures are present in the supplied label excerpts.
“Daily moderate alcohol intake is typically fine if liver tests stay normal in people taking statins.”
No alcohol-specific tolerability language or conditional guidance based on liver test results is present in the supplied label excerpts.
“Both alcohol and Lipitor can raise ALT/AST enzymes.”
The label excerpt addresses Lipitor-associated transaminase elevations, but does not mention alcohol causing ALT/AST elevations in the context of Lipitor.
“Combined heavy alcohol use leads to fatty liver or hepatitis in 5-10% of cases.”
No alcohol-related incidence data (fatty liver/hepatitis) are present in the supplied label excerpts.
“Alcohol worsens statin-induced myalgia.”
The supplied label excerpt discusses myopathy/rhabdomyolysis risk factors and withholding/discontinuation criteria, but does not mention alcohol worsening myalgia.
“Alcohol worsens statin-induced rhabdomyolysis (rare but serious muscle breakdown).”
The supplied label excerpt discusses rhabdomyolysis reports, but does not mention alcohol as a risk factor.
“Alcohol use with Lipitor is associated with higher odds of stomach upset and dizziness.”
No alcohol-associated adverse reactions are present in the supplied label excerpts.
“Alcohol use with Lipitor is associated with poor cholesterol control.”
The supplied label excerpts do not discuss alcohol affecting lipid control with Lipitor.
“People with existing liver disease, obesity, or older age face higher risks when using Lipitor with alcohol.”
The supplied label excerpts include active liver disease contraindication and liver function test recommendations, but do not provide alcohol-specific risk stratification for obesity or older age.
“Doctors often recommend total avoidance of alcohol for people with higher-risk conditions when taking Lipitor.”
No alcohol-avoidance recommendations are present in the supplied label excerpts.
“The American College of Cardiology recommends discussing personal habits with a doctor because individual factors like Lipitor dose (10-80 mg) matter.”
The provided FDA label excerpts do not include ACC recommendations.
“People taking high-dose Lipitor (>40 mg) are advised to avoid alcohol.”
No alcohol advice tied to Lipitor dose is present in the supplied label excerpts.
“People with elevated liver enzymes on prior tests are advised to avoid alcohol when taking Lipitor.”
The label excerpt recommends liver function tests and dose reduction/withdrawal if ALT/AST persist >3x ULN, but does not provide alcohol avoidance guidance.
“People who notice unexplained muscle pain, dark urine, or fatigue are advised to avoid alcohol when taking Lipitor.”
The label excerpt discusses temporary withholding/discontinuation in conditions suggestive of myopathy/risk factors, but does not mention alcohol or specific symptom-triggered alcohol avoidance.
“People with cirrhosis or hepatitis are advised to avoid alcohol when taking Lipitor.”
The supplied label excerpts contraindicate active liver disease, but do not mention cirrhosis/hepatitis or alcohol avoidance.
“People drinking more than 7 drinks per week are advised to avoid alcohol when taking Lipitor.”
No alcohol quantity thresholds are present in the supplied label excerpts.
“Pravastatin or rosuvastatin may have slightly lower liver interaction risks with alcohol than other statins.”
The supplied label excerpts are for Lipitor only and do not provide cross-statin comparisons regarding alcohol.
Contradictions
Low
AI Statement
“Lipitor prescribing information states that moderate alcohol consumption need not be avoided, but excessive intake should be.”
Label Reference
Provided excerpts include liver function test recommendations prior to and at 12 weeks after initiation and periodically thereafter, and contraindicate active liver disease, but do not support any claim that moderate alcohol “need not be avoided.”
Important Omissions
The provided label excerpts specify liver function testing timing (prior to and at 12 weeks after initiation and after dose increases) and dose reduction/withdrawal if ALT/AST increase persists >3x ULN; the AI’s monitoring claim (every 6–12 months) does not reflect the provided timing.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Many alcohol-related claims are not supported by the provided Lipitor label excerpts and include specific thresholds and quantitative risk estimates, which could mislead users about alcohol use and monitoring.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Alcohol-specific claims (moderate vs heavy thresholds, quantitative risk increases, symptom-based alcohol avoidance, and cross-statin comparisons) are not supported by the provided FDA label excerpts; monitoring timing was also misstated.
Suggested Improvement
Restrict statements to what the provided label supports: active liver disease contraindication, liver function test timing (prior to and at 12 weeks after initiation and after dose increases, then periodically), and management of persistent ALT/AST elevations (>3x ULN). Remove or qualify all alcohol-specific guidance, thresholds, and quantitative estimates unless additional FDA label alcohol-related text is provided.